Selank
Selank is a peptide, indexed here under Neuroactive peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Neuroactive peptides |
| CAS registry number | 129954-34-3[1] |
| PubChem CID | 11765600[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C33H57N11O9[1] |
| Molecular weight | 751.9 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Selank is a synthetic heptapeptide described in the retrieved literature as a member of the tuftsin family. A 2018 Protein and Peptide Letters review covers the molecular aspects of its biological activity under the heading of peptide-based anxiolytics, and a 2003 Neuroscience and Behavioral Physiology paper places it with short tuftsin-family peptides in the regulation of adaptive behaviour.
Two routes recur in the retrieved set. A 2001 Bulletin of Experimental Biology and Medicine paper reports an inhibitory effect on enkephalin-degrading enzymes, and a 2001 Bioorganicheskaia Khimiia paper reports the same for Semax and Selank against those enzymes in human serum. Separately, a 2017 Frontiers in Pharmacology paper reports that GABA, Selank and olanzapine affect the expression of genes involved in GABAergic signalling, and a 2021 Journal of Clinical Pharmacology review discusses agents impacting GABA receptors.
[3, 4, 5, 6, 7, 8]Reported mechanism
A tuftsin-family heptapeptide; the retrieved records report inhibition of enkephalin-degrading enzymes and effects on the expression of genes in GABAergic signalling.
[5, 7]Stated in the titles of the cited 2001 Bulletin of Experimental Biology and Medicine and 2017 Frontiers in Pharmacology papers.
Targets named in the cited records: enkephalin-degrading enzymes, GABAergic signalling genes.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Selank appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- tuftsin analogue
- Thr-Lys-Pro-Arg-Pro-Gly-Pro
Where this page sits
Research records
Cited research records for Selank, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include Selank
Compounds indexed next to it
- Semax — Neuroactive peptides
- Cerebrolysin — Neuroactive peptides
- Noopept — Neuroactive peptides
Class page: Neuroactive peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Selank?
Selank is a synthetic heptapeptide described in the retrieved literature as a member of the tuftsin family. A 2018 Protein and Peptide Letters review covers the molecular aspects of its biological activity under the heading of peptide-based anxiolytics, and a 2003 Neuroscience and Behavioral Physiology paper places it with short tuftsin-family peptides in the regulation of adaptive behaviour.
Which class is Selank indexed under?
Selank is indexed under Neuroactive peptides. The compounds grouped here are peptides whose retrieved literature examines effects in the nervous system.
What does the FDA application register show for Selank?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 11765600, Selank. PubChem, National Library of Medicine (2026). pubchem:11765600
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:selank
- Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and peptide letters (2018). pmid:30255741
- Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neuroscience and behavioral physiology (2003). pmid:14969422
- The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of experimental biology and medicine (2001). pmid:11550013
- [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]. Bioorganicheskaia khimiia (2001). pmid:11443939
- GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in pharmacology (2017). pmid:28293190
- Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. Journal of clinical pharmacology (2021). pmid:34396551
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.